The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Claire HarrisonDuring the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub was pleased to speak to Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, What is the rationale for using bromodomain and extraterminal (BET) inhibitors to treat myelofibrosis?
What is the rationale for using BET inhibitors to treat myelofibrosis?
Harrison opens by discussing the unmet needs for patients with myelofibrosis who are unresponsive or intolerant to typical treatments such as ruxolitinib. The clinical applications of BET inhibitors are summarized, including the targeting of nuclear factor kappa B pathways, megakaryopoiesis, and erythropoiesis. Harrison concludes by highlighting the recent advancements in BET inhibitors for this indication and the latest updates published at the ASH Annual Meeting and Exposition.
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?